Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Tineke Casneuf"'
Autor:
Mark Bustoros, Shankara Anand, Romanos Sklavenitis-Pistofidis, Robert Redd, Eileen M. Boyle, Benny Zhitomirsky, Andrew J. Dunford, Yu-Tzu Tai, Selina J. Chavda, Cody Boehner, Carl Jannes Neuse, Mahshid Rahmat, Ankit Dutta, Tineke Casneuf, Raluca Verona, Efstathis Kastritis, Lorenzo Trippa, Chip Stewart, Brian A. Walker, Faith E. Davies, Meletios-Athanasios Dimopoulos, P. Leif Bergsagel, Kwee Yong, Gareth J. Morgan, François Aguet, Gad Getz, Irene M. Ghobrial
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-10 (2022)
Existing clinical models cannot fully capture smoldering multiple myeloma (SMM) heterogeneity. Here, integration of 42 genetic alterations from 214 SMM patients using an unsupervised binary matrix factorization clustering approach results in the iden
Externí odkaz:
https://doaj.org/article/078805a3b909435fb477a229095a08ed
Autor:
Christie P.M. Verkleij, Kristine A. Frerichs, Marloes E.C. Broekmans, Carolien Duetz, Chloe A. O’Neill, Wassilis S.C. Bruins, Paola M. Homan-Weert, Monique C. Minnema, Mark-David Levin, Annemiek Broijl, Gerard M.J. Bos, Marie José Kersten, Saskia K. Klein, Medya M. Shikhagaie, Tineke Casneuf, Yann Abraham, Tina Smets, Greet Vanhoof, Diana Cortes-Selva, Laure van Steenbergen, Elena Ramos, Raluca I. Verona, Maria Krevvata, Pieter Sonneveld, Sonja Zweegman, Tuna Mutis, Niels W.C.J. van de Donk
Publikováno v:
HemaSphere, Vol 7, Iss 5, p e881 (2023)
The CD38-targeting antibody daratumumab has marked activity in multiple myeloma (MM). Natural killer (NK) cells play an important role during daratumumab therapy by mediating antibody-dependent cellular cytotoxicity via their FcγRIII receptor (CD16)
Externí odkaz:
https://doaj.org/article/cf5d724e6de24dcbaeef1516713666db
Autor:
Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay Nooka, Hang Quach, Markus Munder, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, Tineke Casneuf, Nikki DeAngelis, Himal Amin, Jon Ukropec, Rachel Kobos, Maria-Victoria Mateos
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-11 (2020)
Abstract Background Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exh
Externí odkaz:
https://doaj.org/article/f4bcd4b8584c4c2d8d002b323f628268
Autor:
Saad Z. Usmani, Imran Khan, Christopher Chiu, David Foureau, Lawrence J. Druhan, Katherine Rigby, Tineke Casneuf, A. Kate Sasser
Publikováno v:
Experimental Hematology & Oncology, Vol 7, Iss 1, Pp 1-7 (2018)
Abstract Background Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor and immunomodulatory mechanisms of action, demonstrated clinical benefit as monotherapy or in combination with established regimens in patients with multiple m
Externí odkaz:
https://doaj.org/article/63f9548ed8764b44a0ec2f40c21a829d
Autor:
Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay K. Nooka, Hang Quach, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Emma C. Scott, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, David Soong, Tineke Casneuf, Christopher Chiu, Himal Amin, Ming Qi, Piruntha Thiyagarajah, A. Kate Sasser, Jordan M. Schecter, Maria-Victoria Mateos
Publikováno v:
Haematologica, Vol 103, Iss 12 (2018)
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or
Externí odkaz:
https://doaj.org/article/a34eb4051074415eaed565a3bdec8188
Autor:
Meletios A. Dimopoulos, Jesus San-Miguel, Andrew Belch, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kim, Naoki Takezako, Philippe Moreau, Jonathan L. Kaufman, Heather J. Sutherland, Marc Lalancette, Hila Magen, Shinsuke Iida, Jin Seok Kim, H. Miles Prince, Tara Cochrane, Albert Oriol, Nizar J. Bahlis, Ajai Chari, Lisa O’Rourke, Kaida Wu, Jordan M. Schecter, Tineke Casneuf, Christopher Chiu, David Soong, A. Kate Sasser, Nushmia Z. Khokhar, Hervé Avet-Loiseau, Saad Z. Usmani
Publikováno v:
Haematologica, Vol 103, Iss 12 (2018)
In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include
Externí odkaz:
https://doaj.org/article/34bc86c721f547c0b175882c23aa9838